"Only 50/50" Chance of US Medicare Reform Soon

4 November 1996

If the USA continues with a split government, as seems likely, the chances of Medicare reform is no more than 50/50 in the short term, says Gail Wilensky, John M Olin Senior Fellow with Project Hope, and a former Administrator of the US Health Care Financing Administration.

She told the annual assembly of the International Federation of Pharmaceutical Manufacturers Associations in Vienna last month (Marketletter October 21) that chances of reform are no greater because: - there is unlikely to be any action to force such a move next year; - the elderly prefer the present system; - there is no consensus about what to do with the "baby-boomers" (the population bulge born during 1945-65 who start retiring in 2010); and - the "X generation" of twentysomethings does not seem to care.

Nevertheless, Medicare is now a particularly vexing budgetary issue, given the long-term pressures that will come from the retirement of the baby-boomers and, more immediately, the impending bankruptcy of the Medicare Hospital Insurance (Part A) Trust Fund, said Dr Wilensky.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight